State of New Jersey Common Pension Fund D Sells 3,459 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

State of New Jersey Common Pension Fund D trimmed its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 54,350 shares of the biopharmaceutical company’s stock after selling 3,459 shares during the period. State of New Jersey Common Pension Fund D owned about 0.08% of Celldex Therapeutics worth $2,011,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of CLDX. Victory Capital Management Inc. acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at $288,000. Charles Schwab Investment Management Inc. boosted its position in Celldex Therapeutics by 13.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 409,391 shares of the biopharmaceutical company’s stock valued at $16,236,000 after buying an additional 47,844 shares in the last quarter. UBS Group AG boosted its position in Celldex Therapeutics by 645.9% in the fourth quarter. UBS Group AG now owns 158,092 shares of the biopharmaceutical company’s stock valued at $6,270,000 after buying an additional 136,897 shares in the last quarter. Trexquant Investment LP bought a new stake in Celldex Therapeutics during the fourth quarter worth about $1,246,000. Finally, Aigen Investment Management LP acquired a new stake in shares of Celldex Therapeutics during the fourth quarter worth approximately $251,000.

Analyst Upgrades and Downgrades

CLDX has been the topic of a number of research analyst reports. Stifel Nicolaus initiated coverage on Celldex Therapeutics in a research report on Tuesday, June 18th. They set a “buy” rating and a $58.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Monday, September 16th. Wolfe Research started coverage on shares of Celldex Therapeutics in a report on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price objective on the stock. Finally, Wells Fargo & Company boosted their target price on shares of Celldex Therapeutics from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $63.83.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $41.24 on Friday. The company’s 50 day simple moving average is $38.54 and its 200 day simple moving average is $38.74. Celldex Therapeutics, Inc. has a fifty-two week low of $22.11 and a fifty-two week high of $53.18. The firm has a market capitalization of $2.72 billion, a P/E ratio of -14.47 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $1.13 million. Sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.5 EPS for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.